Celcuity rockets after positive trial results on breast cancer combo treatment

Celcuity rose more than 200% in early trading after it reported positive results in late-stage trials for its breast cancer combination treatment.

The trial studied how Celcuity’s gedatolisib worked alongside other treatments made by AstraZeneca and Pfizer. When taking the the three drugmakers’ treatments at the same time, death and progression of the disease dropped, Celcuity announced Monday.

The Minneapolis-based company said it expects to submit gedatolisib for approval by the Food and Drug Administration by the end of the year. The company currently has no drugs on the market and has reported no revenue.